Noninfectious pulmonary complications following hematopoietic stem cell transplantation
10.3969/j.issn.2095-4344.2015.10.028
- VernacularTitle:造血干细胞移植后非感染性肺部并发症：研究与进展
- Author:
Hong LUO
;
Hongbin ZHANG
- Publication Type:Journal Article
- Keywords:
Hematopoietic Stem Cel Transplantation;
Lung Diseases;
Bronchoalveolar Lavage
- From:
Chinese Journal of Tissue Engineering Research
2015;(10):1630-1634
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Hematopoietic stem cel transplantation is a promising treatment for a variety of malignant and nonmalignant disorders. But noninfectious pulmonary complications folowing hematopoietic stem cel transplantation are a major cause of morbidity and mortality in these patients. And the diagnosis and treatment are difficult. OBJECTIVE: To review the noninfectious pulmonary complications after hematopoietic stem cel transplantation in terms of onset time, risk factors, clinical manifestations, characteristics of the high-resolution CT, histopathological measurement, related genes and treatment options. METHODS: A computer-based search of VIP, PubMed and Sciencedirect databases was performed for articles related to noninfectious pulmonary compli cations after hematopoietic stem cel transplantation published from January 2005 to October 2014. The key words were “HSCT, pulmonary complications, non-infectious, pirfenidone” in Chinese and English in the title and abstract. Finaly, 31 articles were included in result analysis. RESULTS AND CONCLUSION: The incidence of noninfectious pulmonary complications after hematopoietic stem cel transplantation has become more and more, with atypical clinical manifestations and limited diagnosis and treatments. According to the different clinical onset time, diagnostic criteria, clinical manifestations and the appropriate laboratory tests, clinicians can make early diagnosis and early intervention. Especialy, the usage of high-resolution chest CT and bronchofiberscope for bronchoalveolar lavage as wel as the timely drug administration can improve the survival rate of patients with noninfectious pulmonary complications after hematopoietic stem cel transplantation.
